Last reviewed · How we verify
NCT02921646: EnergiePancrea
Relationship Between Evolution of Resting Energy Expenditure and Tumoral Response to Chemotherapy in Patients Suffering From Pancreas Cancer
NA trial testing Measure of resting energetic expenditure in Metastatic Pancreatic Cancer in 8 participants. Terminated before completion.
10 July 2019
Quick facts
| Lead sponsor | Center Eugene Marquis |
|---|---|
| Phase | NA |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | other |
| Enrollment | 8 |
| Start date | 10 July 2017 |
| Primary completion | 10 July 2019 |
| Estimated completion | 10 July 2019 |
| Sites | 1 location across France |
Drugs / interventions tested
- Measure of resting energetic expenditure
Conditions studied
- Metastatic Pancreatic Cancer — all drugs for Metastatic Pancreatic Cancer →
Sponsor
Center Eugene Marquis — full company profile →
Who can join
18 and older, any sex, with Metastatic Pancreatic Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to determine whether evolution of resting energetic expenditure is a predictive marker of tumoral response for patients suffering from metastatic pancreatic cancer and treated with 1st line of chemotherapy.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT02921646
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Metastatic Pancreatic Cancer
Currently open trials in the same condition.
- NCT07409272 — A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherap · Phase 3 · recruiting
- NCT06861088 — The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer · Phase 3 · recruiting
- NCT06843551 — The Miami "EMPIRE" Trial - Eradication of Metastatic Pancreatic Cancer With Immuno-Radiation · Phase 2 · recruiting
- NCT06951997 — QL1706 Plus Chidamide, AG as First-line Treatment for Metastatic Pancreatic Cancer · Phase 2 · recruiting
- NCT06533332 — A Phase 1 Trial of ERX-315 in Participants With Advanced Solid Tumors · Phase 1 · recruiting
Other Center Eugene Marquis trials
Trials by the same sponsor.
- NCT07189598 — Phase III Adaptive Adaptive Stereostactic Body Radiotherapy (SBRT) With Dose Escalation for High-Risk Prostate Cancer · NA · recruiting
- NCT07122089 — Evaluation of SIRT Followed by Immunotherapy for Treatment of Hepatocellular Carcinoma With Portal Vein Thrombosis · Phase 2 · not yet recruiting
- NCT06551272 — Microbiota Modification for Immuno-oncology in Hepatocellular Carcinoma · Phase 2 · recruiting
- NCT06627075 — Optical Surface Guidance for External Radiotherapy of Head and Neck Cancer · NA · recruiting
- NCT06583460 — Systematic Intervention to Improve Sexual Dysfunction · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02921646 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Center Eugene Marquis
- Last refreshed: 27 January 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02921646.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing